The Current Ratio as of December 2024 (TTM) for argenx SE (ARGX) is 8.53

According to argenx SE’s latest financial reports and current stock price. The company's current Current Ratio is 8.53. This represents a change of 86.71% compared to the average of 4.57 of the last 4 quarters.

argenx SE (ARGX) Historical Current Ratio (quarterly & annually)

How has ARGX Current Ratio performed in the past?

The mean historical Current Ratio of argenx SE over the last ten years is 8.49. The current 8.53 Current Ratio has changed 9.95% with respect to the historical average. Over the past ten years (40 quarters), ARGX's Current Ratio was at its highest in in the December 2018 quarter at 14.29. The Current Ratio was at its lowest in in the March 2015 quarter at 0.

argenx SE (ARGX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of argenx SE Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

argenx SE (ARGX) Average Current Ratio

How has ARGX Current Ratio performed in the past?

The current Current Ratio of argenx SE (ARGX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

argenx SE (ARGX) Current Ratio vs. Peers

How is ARGX’s Current Ratio compared to its peers?

argenx SE’s Current Ratio is less than IVERIC bio, Inc. (18.63), greater than Blueprint Medicines Corporation (3.32), greater than Amylyx Pharmaceuticals, Inc. (4.55), less than Karuna Therapeutics, Inc. (19.31), less than Day One Biopharmaceuticals, Inc. (14.62), greater than Mirati Therapeutics, Inc. (7.54), less than Terns Pharmaceuticals, Inc. (32.99), greater than Apellis Pharmaceuticals, Inc. (4.36), greater than Legend Biotech Corporation (4.98), greater than Zai Lab Limited (3.01), greater than Seagen Inc. (2.67), greater than Alnylam Pharmaceuticals, Inc. (2.75), greater than Ascendis Pharma A/S (1.16), less than Vaxcyte, Inc. (17.88), greater than Travere Therapeutics, Inc. (1.71), less than Akero Therapeutics, Inc. (17.25), greater than BeiGene, Ltd. (1.93),

Build a custom stock screener for argenx SE (ARGX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like argenx SE using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

argenx SE (ARGX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like argenx SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.